Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 26131 | 2.75 |
09:34 ET | 5195 | 2.76 |
09:36 ET | 16051 | 2.78 |
09:38 ET | 14150 | 2.755 |
09:39 ET | 1600 | 2.75 |
09:41 ET | 3800 | 2.7312 |
09:43 ET | 190 | 2.74 |
09:45 ET | 5948 | 2.745 |
09:48 ET | 2866 | 2.725 |
09:52 ET | 6810 | 2.755 |
09:54 ET | 200 | 2.755 |
09:56 ET | 3528 | 2.75 |
09:57 ET | 4797 | 2.725 |
09:59 ET | 500 | 2.7201 |
10:01 ET | 10552 | 2.73 |
10:03 ET | 4645 | 2.705 |
10:06 ET | 5356 | 2.675 |
10:08 ET | 200 | 2.675 |
10:10 ET | 2349 | 2.67 |
10:12 ET | 1448 | 2.675 |
10:14 ET | 12880 | 2.685 |
10:15 ET | 1227 | 2.685 |
10:17 ET | 600 | 2.685 |
10:19 ET | 300 | 2.68 |
10:21 ET | 3833 | 2.675 |
10:24 ET | 15643 | 2.685 |
10:26 ET | 550 | 2.685 |
10:28 ET | 200 | 2.685 |
10:30 ET | 100 | 2.685 |
10:32 ET | 18018 | 2.67 |
10:33 ET | 2733 | 2.6691 |
10:35 ET | 8371 | 2.66 |
10:37 ET | 16147 | 2.645 |
10:39 ET | 801 | 2.645 |
10:42 ET | 8880 | 2.645 |
10:44 ET | 100 | 2.645 |
10:46 ET | 750 | 2.645 |
10:48 ET | 300 | 2.645 |
10:50 ET | 700 | 2.64 |
10:51 ET | 6501 | 2.635 |
10:53 ET | 1033 | 2.635 |
10:55 ET | 2482 | 2.63 |
10:57 ET | 300 | 2.625 |
11:02 ET | 100 | 2.62 |
11:04 ET | 29600 | 2.635 |
11:06 ET | 3099 | 2.625 |
11:08 ET | 200 | 2.625 |
11:09 ET | 2166 | 2.625 |
11:11 ET | 200 | 2.625 |
11:13 ET | 1000 | 2.625 |
11:15 ET | 900 | 2.625 |
11:18 ET | 6121 | 2.63 |
11:20 ET | 700 | 2.635 |
11:22 ET | 100 | 2.635 |
11:24 ET | 6279 | 2.645 |
11:26 ET | 600 | 2.645 |
11:27 ET | 300 | 2.645 |
11:29 ET | 1700 | 2.645 |
11:31 ET | 400 | 2.645 |
11:33 ET | 1733 | 2.645 |
11:36 ET | 4674 | 2.635 |
11:38 ET | 200 | 2.635 |
11:44 ET | 100 | 2.635 |
11:45 ET | 300 | 2.635 |
11:47 ET | 1866 | 2.635 |
11:51 ET | 1876 | 2.635 |
11:54 ET | 14260 | 2.655 |
11:56 ET | 2704 | 2.655 |
11:58 ET | 200 | 2.66 |
12:00 ET | 1000 | 2.655 |
12:02 ET | 2300 | 2.655 |
12:03 ET | 1150 | 2.655 |
12:05 ET | 100 | 2.655 |
12:07 ET | 1066 | 2.655 |
12:09 ET | 7949 | 2.645 |
12:14 ET | 600 | 2.645 |
12:16 ET | 100 | 2.645 |
12:18 ET | 8962 | 2.645 |
12:20 ET | 100 | 2.645 |
12:21 ET | 347 | 2.645 |
12:23 ET | 11564 | 2.645 |
12:25 ET | 300 | 2.64 |
12:27 ET | 883 | 2.645 |
12:30 ET | 9297 | 2.635 |
12:32 ET | 1000 | 2.635 |
12:34 ET | 300 | 2.635 |
12:36 ET | 200 | 2.63 |
12:38 ET | 1133 | 2.635 |
12:39 ET | 554 | 2.635 |
12:41 ET | 100 | 2.635 |
12:43 ET | 11723 | 2.635 |
12:45 ET | 600 | 2.635 |
12:48 ET | 7948 | 2.635 |
12:50 ET | 300 | 2.635 |
12:52 ET | 15458 | 2.635 |
12:54 ET | 500 | 2.63 |
12:56 ET | 512 | 2.635 |
12:57 ET | 1042 | 2.635 |
12:59 ET | 200 | 2.63 |
01:01 ET | 243 | 2.635 |
01:03 ET | 600 | 2.635 |
01:06 ET | 500 | 2.6375 |
01:08 ET | 10000 | 2.6208 |
01:10 ET | 500 | 2.62 |
01:14 ET | 1746 | 2.625 |
01:15 ET | 100 | 2.6254 |
01:17 ET | 1045 | 2.625 |
01:19 ET | 800 | 2.625 |
01:24 ET | 3800 | 2.62 |
01:26 ET | 300 | 2.625 |
01:28 ET | 1400 | 2.625 |
01:30 ET | 100 | 2.625 |
01:32 ET | 12274 | 2.61 |
01:33 ET | 6809 | 2.615 |
01:35 ET | 700 | 2.6101 |
01:37 ET | 1921 | 2.6125 |
01:39 ET | 2775 | 2.615 |
01:42 ET | 1071 | 2.615 |
01:44 ET | 1450 | 2.615 |
01:46 ET | 319 | 2.615 |
01:48 ET | 780 | 2.615 |
01:50 ET | 605 | 2.615 |
01:51 ET | 1130 | 2.61 |
01:53 ET | 1919 | 2.615 |
01:55 ET | 500 | 2.615 |
01:57 ET | 500 | 2.6125 |
02:00 ET | 614 | 2.615 |
02:02 ET | 500 | 2.615 |
02:04 ET | 1345 | 2.615 |
02:06 ET | 100 | 2.615 |
02:08 ET | 200 | 2.6125 |
02:11 ET | 400 | 2.615 |
02:13 ET | 2509 | 2.615 |
02:15 ET | 1213 | 2.61 |
02:18 ET | 886 | 2.615 |
02:20 ET | 3990 | 2.6149 |
02:22 ET | 675 | 2.615 |
02:24 ET | 2267 | 2.6125 |
02:26 ET | 909 | 2.615 |
02:27 ET | 100 | 2.6125 |
02:29 ET | 1937 | 2.615 |
02:31 ET | 500 | 2.615 |
02:33 ET | 1797 | 2.615 |
02:36 ET | 819 | 2.6125 |
02:38 ET | 1050 | 2.615 |
02:40 ET | 600 | 2.615 |
02:42 ET | 4732 | 2.61 |
02:44 ET | 1400 | 2.615 |
02:45 ET | 25734 | 2.61 |
02:49 ET | 300 | 2.615 |
02:51 ET | 995 | 2.615 |
02:54 ET | 2497 | 2.615 |
02:56 ET | 300 | 2.62 |
02:58 ET | 1218 | 2.61 |
03:00 ET | 700 | 2.615 |
03:02 ET | 5025 | 2.615 |
03:03 ET | 35734 | 2.6 |
03:05 ET | 100 | 2.605 |
03:07 ET | 200 | 2.605 |
03:09 ET | 505 | 2.605 |
03:12 ET | 5382 | 2.6 |
03:14 ET | 206 | 2.605 |
03:16 ET | 2910 | 2.6 |
03:18 ET | 389 | 2.605 |
03:20 ET | 1899 | 2.605 |
03:21 ET | 2023 | 2.605 |
03:23 ET | 93039 | 2.605 |
03:25 ET | 909 | 2.605 |
03:27 ET | 2028 | 2.6025 |
03:30 ET | 809 | 2.6 |
03:32 ET | 24906 | 2.59 |
03:34 ET | 10269 | 2.585 |
03:36 ET | 474 | 2.585 |
03:38 ET | 1076 | 2.585 |
03:39 ET | 338 | 2.5875 |
03:41 ET | 1372 | 2.585 |
03:43 ET | 2223 | 2.585 |
03:45 ET | 16645 | 2.585 |
03:48 ET | 45595 | 2.6 |
03:50 ET | 7661 | 2.605 |
03:52 ET | 5572 | 2.605 |
03:54 ET | 5167 | 2.605 |
03:56 ET | 8025 | 2.605 |
03:57 ET | 13574 | 2.605 |
03:59 ET | 29557 | 2.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 766.2M | -8.3x | --- |
Cogent Biosciences Inc | 765.9M | -3.6x | --- |
Viridian Therapeutics Inc | 762.7M | -2.6x | --- |
89Bio Inc | 777.2M | -4.1x | --- |
Prime Medicine Inc | 777.8M | -3.0x | --- |
Scholar Rock Holding Corp | 748.9M | -4.7x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $766.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.42 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.